A Multicenter Randomized Double-Blind Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn s Disease

Go Back to All Clinical Trials

A Multicenter Randomized Double-Blind Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn s Disease

Brief description of study

The purpose of this study is to assess an investigational drug called etrasimod (also referred to as the “study drug”) in the treatment of Crohn’s disease (CD). “Investigational” means that etrasimod has not been approved by any regulatory authorities, including the US Food and Drug Administration (FDA), therefore, it is not available by prescription.

Clinical Study Identifier: s21-00122

ClinicalTrials.gov Identifier: NCT04173273

Principal Investigator: David P Hudesman.

Other Investigators: Adam Faye, Simon J Hong, Jordan E Axelrad, Shannon Chang.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies